SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 31, 2006--Hana Biosciences (NASDAQ:HNAB - News):
Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, will present pivotal trials on their most advanced drug candidate, Zensana(TM) (ondansetron HCl) Oral Spray. As previously reported, pivotal trials were completed in early 2006 and the company believes endpoints were met for a New Drug Application (NDA) under section 505(b)(2). Hana remains on track for a submission in the second quarter of 2006; and, upon potential approval by the FDA, the company is targeting a Zensana(TM) U.S. launch in 2007.
